The Influence of Serum Methotrexate Concentrations and Drug Dosage on Outcome In Childhood Acute Lymphoblastic Leukaemia
1992
Concerns About Methotrexate Study in Childhood Leukemia
Commentary
Author Information
Author(s): Walter Cosolo, Jim Siderov, John Zalcberg
Primary Institution: Heidelberg Repatriation Hospital
Conclusion
The authors argue that the study's methodology for calculating methotrexate clearance is flawed, which undermines its conclusions about pharmacokinetics in childhood acute lymphoblastic leukemia.
Supporting Evidence
- The authors highlight that the study used areas integrated to less than infinity for calculating drug clearance, which is not acceptable.
- They suggest that plasma samples should have been collected for approximately 40 hours instead of 24 to accurately estimate pharmacokinetic parameters.
- The commentary emphasizes that the median plasma methotrexate concentration is not useful for correlating pharmacokinetic parameters with treatment response.
Takeaway
The way the study measured methotrexate levels might be wrong, so we can't trust its findings about how the drug works in kids with leukemia.
Methodology
The authors critique the study's use of inadequate time points for measuring drug clearance and plasma concentrations.
Limitations
The study's conclusions are based on incorrectly calculated pharmacokinetic parameters.
Statistical Information
Confidence Interval
95%
Want to read the original?
Access the complete publication on the publisher's website